Pharmaceuticals, Biotechnology & Life Sciences

Read how Bayer’s shares slipped ahead of a U.S. glyphosate trial, with investors weighing potential settlements and the broader market’s geopolitical backdrop.

Merck KGaA’s latest earnings reveal steady €20 bn revenues and €4 bn net income, while a strategic partnership with Remepy blends biologics with AI‑driven digital therapeutics, positioning the company to navigate patent cliffs, secure payer value, a…

Pfizer’s Vyndamax patent settlement extends exclusivity to 2031, boosting revenue and positioning the drug amid rising competition and value‑based pricing shifts.

Johnson & Johnson cuts clinical‑documentation time from 700 hrs to 15 mins with AI, slashing costs and speeding drug launches – investors see a modest, optimistic uptick.

Danaher Corp. directors’ phantom‑share conversions revealed in SEC Form 4 filings—insider ownership, governance, and impact on shareholders explained.

West Pharmaceutical Services surges after strong Q1 earnings, citing cost‑efficient manufacturing, global expansion and new injection device tech—read why analysts see a “strong buy” trend.

Explore how United Therapeutics’ CEO trading plan reveals key insights into capital discipline, executive incentives, and regulatory compliance in the specialty‑pharma sector.

Amgen’s institutional investor confidence and DCF valuation reveal robust growth, efficient R&D spend, and a 21.5% profit margin, positioning the biotech firm favorably amid evolving value‑based reimbursement models.

Swedish Orphan Biovitrum (Sobi) tops Q1 expectations with double‑digit haemophilia and immunology growth, strong EBITDA, and a solid pipeline for future earnings momentum.

Novartis Q1 2024 earnings miss reveals generic pressure and pipeline promise – a deep dive into pricing, patent cliffs, M&A and future growth.